Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear

The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.

Hantson_Ludwig_1200x675 — Alexion CEO Ludwig Hantson

Alexion Pharmaceuticals Inc.’s new CEO Ludwig Hantson will need to refocus the rare disease specialist onto a steady growth track after the company's recent missteps. Alexion announced the appointment of Hantson, formerly Baxalta Inc.'s CEO, on March 27.

Hantson succeeds David Brennan, who stepped in on an interim basis in December after former CEO David Hallal resigned for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bluebird Builds Out Leadership Team Under Private Equity Ownership

02 Jul 2025

• By Jessica Merrill

The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

02 Jul 2025

• By Anju Ghangurde

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Quotables: Pharma Leaders On The Month’s Hot Topics

30 Jun 2025

• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

What Incyte Investors Expect From New CEO Bill Meury

27 Jun 2025

• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

02 Jul 2025

• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.